Key points from article :
The U.S. Food and Drug Administration (FDA) has approved remestemcel-L-rknd (Ryoncil), marking the first FDA-approved mesenchymal stromal cell (MSC) therapy. This treatment is designed for pediatric patients aged two months and older suffering from steroid-refractory acute graft versus host disease (SR-aGVHD), a severe complication that can occur after a stem cell transplant when the donor's immune cells attack the recipient’s tissues.
In a clinical trial involving 54 children, Ryoncil demonstrated a 70% overall response rate by Day 28, with 30% achieving a complete response and 41% showing partial improvement. The median duration of response was 54 days. While the treatment was generally well-tolerated, common side effects included infections, fever, bleeding, swelling, and high blood pressure.
Ryoncil has received fast track, orphan drug, and priority review designations from the FDA, highlighting its importance as a breakthrough therapy for a serious condition. The approval offers hope for children with limited treatment options, providing a new approach to managing SR-aGVHD when steroids fail.
